Toshihiro Wajima
Overview
Explore the profile of Toshihiro Wajima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
696
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamaguchi D, Katsube T, Wajima T
Pharmacol Res Perspect
. 2024 Aug;
12(5):e70001.
PMID: 39180172
When planning pediatric clinical trials, optimizing the sample size of neonates/infants is essential because it is difficult to enroll these subjects. In this simulation study, we evaluated the sample size...
2.
Yokokawa Shibata R, Kubota R, Uenaka K, Kaibara A, Wajima T
Drug Metab Pharmacokinet
. 2023 May;
51:100496.
PMID: 37244205
The objectives of this analysis were to characterize the pharmacokinetics of duloxetine in Japanese pediatric patients aged 9-17 years with major depressive disorder (MDD) and to explore potential intrinsic factors...
3.
Wenzler E, Butler D, Tan X, Katsube T, Wajima T
Clin Pharmacokinet
. 2022 Jun;
61(7):1069.
PMID: 35661333
No abstract available.
4.
Wenzler E, Butler D, Tan X, Katsube T, Wajima T
Clin Pharmacokinet
. 2021 Nov;
61(4):539-552.
PMID: 34792787
Background: The need for continuous renal replacement therapy (CRRT) in critically ill patients with serious infections is associated with clinical failure, emergence of resistance, and excess mortality. These poor outcomes...
5.
Kawaguchi N, Katsube T, Echols R, Wajima T, Nicolau D
J Clin Pharmacol
. 2021 Oct;
62(5):670-680.
PMID: 34648652
Cefiderocol is a siderophore cephalosporin for the treatment of infections caused by gram-negative bacteria including carbapenem-resistant strains. The aim of this study was to develop an intrapulmonary pharmacokinetic (PK) model...
6.
Katsube T, Nicolau D, Rodvold K, Wunderink R, Echols R, Matsunaga Y, et al.
J Antimicrob Chemother
. 2021 Sep;
76(11):3069.
PMID: 34532730
No abstract available.
7.
Katsube T, Nicolau D, Rodvold K, Wunderink R, Echols R, Matsunaga Y, et al.
J Antimicrob Chemother
. 2021 Aug;
76(11):2902-2905.
PMID: 34383901
Objectives: Lung penetration of cefiderocol, a novel siderophore cephalosporin approved for treatment of nosocomial pneumonia, has previously been evaluated in healthy subjects. This study assessed the intrapulmonary pharmacokinetic profile of...
8.
Katsube T, Wajima T
J Pharmacokinet Pharmacodyn
. 2021 Aug;
48(6):851-860.
PMID: 34347231
In pharmacometrics, understanding a covariate effect on an interested outcome is essential for assessing the importance of the covariate. Variance-based global sensitivity analysis (GSA) can simultaneously quantify contribution of each...
9.
Shimizu R, Katsube T, Wajima T
CPT Pharmacometrics Syst Pharmacol
. 2021 Apr;
10(5):489-499.
PMID: 33797208
Platelets are produced by hematopoietic stem cells via megakaryocytes in the bone marrow and play a critical role in hemostasis. The aim of this study was to develop a new...
10.
Kawaguchi N, Katsube T, Echols R, Wajima T
Antimicrob Agents Chemother
. 2020 Dec;
65(3).
PMID: 33257454
Cefiderocol is a novel siderophore cephalosporin with antibacterial activity against Gram-negative bacteria, including carbapenem-resistant strains. The standard dosing regimen of cefiderocol is 2 g administered every 8 hours over 3 ...